ATE507817T1 - Partikel - Google Patents
PartikelInfo
- Publication number
- ATE507817T1 ATE507817T1 AT06820366T AT06820366T ATE507817T1 AT E507817 T1 ATE507817 T1 AT E507817T1 AT 06820366 T AT06820366 T AT 06820366T AT 06820366 T AT06820366 T AT 06820366T AT E507817 T1 ATE507817 T1 AT E507817T1
- Authority
- AT
- Austria
- Prior art keywords
- particles
- enzyme
- cleaved
- linkers
- linked
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Glanulating (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0524313.4A GB0524313D0 (en) | 2005-11-29 | 2005-11-29 | Particles |
PCT/GB2006/004459 WO2007063300A2 (en) | 2005-11-29 | 2006-11-29 | Particles |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE507817T1 true ATE507817T1 (de) | 2011-05-15 |
Family
ID=35601447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06820366T ATE507817T1 (de) | 2005-11-29 | 2006-11-29 | Partikel |
Country Status (8)
Country | Link |
---|---|
US (1) | US8318206B2 (de) |
EP (1) | EP1957038B8 (de) |
JP (1) | JP5173827B2 (de) |
AT (1) | ATE507817T1 (de) |
DE (1) | DE602006021783D1 (de) |
ES (1) | ES2365536T3 (de) |
GB (1) | GB0524313D0 (de) |
WO (1) | WO2007063300A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
DK1994155T4 (da) | 2006-02-13 | 2022-07-25 | Daiichi Sankyo Co Ltd | Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering |
GB0618524D0 (en) * | 2006-09-20 | 2006-11-01 | Isis Innovation | Multimeric particles |
JP2010007169A (ja) * | 2008-06-30 | 2010-01-14 | Kyushu Univ | 金微粒子とその製造方法、およびその用途 |
WO2010046377A2 (en) * | 2008-10-23 | 2010-04-29 | Fundació Privada Institut Català De Nanotecnologia | Immunoactivating conjugates comprising nanoparticles coated with peptides |
EP2403964B1 (de) | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Verfahren und produkte zur in-vivo-profilerstellung von enzymen |
US20110123452A1 (en) * | 2009-11-25 | 2011-05-26 | Nanoprobes, Inc. | Metal oligomers and polymers and their use in biology and medicine |
GB201004306D0 (en) * | 2010-03-15 | 2010-04-28 | Imp Innovations Ltd | Assay |
US20130089739A1 (en) * | 2011-10-07 | 2013-04-11 | King Abdullah University of Science and Technology (KAUST) | Nanostructured metal oxides and mixed metal oxides, methods of making these nanoparticles, and methods of their use |
US8809435B2 (en) | 2012-05-16 | 2014-08-19 | The United States Of America As Represented By The Secretary Of The Army | Process enhancement via stimuli responsive particle surfaces |
WO2013185032A1 (en) * | 2012-06-07 | 2013-12-12 | President And Fellows Of Harvard College | Nanotherapeutics for drug targeting |
WO2014012165A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
CN118010994A (zh) | 2013-06-07 | 2024-05-10 | 麻省理工学院 | 基于亲和力检测配体编码的合成性生物标记物 |
EP3149484A1 (de) * | 2014-05-30 | 2017-04-05 | IMRA America, Inc. | Auf goldnanopartikeln basierender kolorimetrischer diagnosetest zur detektion von proteasen und proteaseinhibitoren |
US10583104B2 (en) * | 2014-08-06 | 2020-03-10 | Indiana University Research And Technology Corporation | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis |
CN107843736A (zh) * | 2017-09-15 | 2018-03-27 | 山东博奥克生物科技有限公司 | 一种胶体金早孕检测试剂及其制备方法 |
WO2020150560A1 (en) | 2019-01-17 | 2020-07-23 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002320058A1 (en) | 2001-06-06 | 2002-12-16 | The General Hspital Corporation | Magnetic-nanoparticle conjugates and methods of use |
US7485419B2 (en) | 2004-01-13 | 2009-02-03 | The Board Of Trustees Of The University Of Illinois | Biosensors based on directed assembly of particles |
EP1812864A2 (de) * | 2004-10-07 | 2007-08-01 | Emory University | Multifunktionale nanopartikelkonjugate und ihre verwendung |
-
2005
- 2005-11-29 GB GBGB0524313.4A patent/GB0524313D0/en not_active Ceased
-
2006
- 2006-11-29 AT AT06820366T patent/ATE507817T1/de not_active IP Right Cessation
- 2006-11-29 ES ES06820366T patent/ES2365536T3/es active Active
- 2006-11-29 DE DE602006021783T patent/DE602006021783D1/de active Active
- 2006-11-29 JP JP2008542827A patent/JP5173827B2/ja not_active Expired - Fee Related
- 2006-11-29 EP EP06820366A patent/EP1957038B8/de not_active Not-in-force
- 2006-11-29 US US12/095,408 patent/US8318206B2/en not_active Expired - Fee Related
- 2006-11-29 WO PCT/GB2006/004459 patent/WO2007063300A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1957038B8 (de) | 2011-09-21 |
EP1957038A2 (de) | 2008-08-20 |
GB0524313D0 (en) | 2006-01-04 |
ES2365536T3 (es) | 2011-10-06 |
WO2007063300A3 (en) | 2007-10-25 |
EP1957038B1 (de) | 2011-05-04 |
US20090181097A1 (en) | 2009-07-16 |
WO2007063300A2 (en) | 2007-06-07 |
JP5173827B2 (ja) | 2013-04-03 |
JP2009517452A (ja) | 2009-04-30 |
US8318206B2 (en) | 2012-11-27 |
DE602006021783D1 (de) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE507817T1 (de) | Partikel | |
WO2008073162A3 (en) | Lysine acetylation sites | |
EA200800952A1 (ru) | Конъюгаты антитело-лекарство и способы применения | |
MX2009007290A (es) | Compuestos agonistas del receptor de la proteina 1 similar al glucagon. | |
TR201000668T1 (tr) | Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati | |
IN2012DN03025A (de) | ||
MA33892B1 (fr) | Anticorps anti-her3, et leurs utilisations | |
CY1114746T1 (el) | Ποτα πρωτεϊνης που εχουν υποστει οξινιση και περιεχουν εναιωρουμενα σωματιδια και μεθοδοι παρασκευης τους | |
EA200601670A1 (ru) | Конъюгаты гидроксиалкилкрахмала и белка | |
NO20083062L (no) | Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1 | |
WO2007105027A8 (en) | Anticancer drugs conjugated to antibody via an enzyme cleavable linker | |
CY1113206T1 (el) | Μεθοδος παρασκευης προϊοντος συζευξης αντισωματος maytansinoid | |
DE602005026789D1 (de) | Le | |
DE602004025101D1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
ATE497976T1 (de) | Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren | |
NZ592432A (en) | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) | |
EA200702193A1 (ru) | Гликозилирование белков | |
NO20082240L (no) | GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser | |
WO2008013948A3 (en) | Tyrosine phosphorylation sites | |
NO20091181L (no) | Anti-C5AR-antistoffer med forbedrede egenskaper | |
CY1114023T1 (el) | Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog | |
WO2008054597A3 (en) | Tyrosine phosphorylation sites | |
ATE556071T1 (de) | Kappa-opioidrezeptor-liganden | |
WO2006078648A3 (en) | Rhinovirus vaccines | |
WO2008013934A8 (en) | Tyrosine phosphorylation sites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |